Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.

被引：0
|
作者：
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, A. Eli
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur S.
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos Gabor
Viqueira, Andrea
Lesokhin, Alexander M.
机构：
[1] Sorbonne Univ, Hop St Antoine, Paris, France
[2] INSERM UMRs938, Paris, France
[3] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA
[4] Hop St Louis, Paris, France
[5] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[6] Epworth Healthcare, Melbourne, Vic, Australia
[7] Weill Cornell Med Coll, New York Presbyterian Hosp, New York, NY USA
[8] Univ Navarra Clin, Madrid, Spain
[9] Hosp Univ 12 OCTUBRE, Madrid, Spain
[10] Miami Canc Inst, Miami, FL USA
[11] Indiana Blood & Marrow Transplant, Indianapolis, IN USA
[12] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[13] Norton Canc Inst, Louisville, KY USA
[14] Emory Univ Hosp, Winship Canc Inst, Atlanta, GA USA
[15] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[16] Nagoya City Univ, Dept Hematol & Oncol, Grad Sch Med Sci, Nagoya, Aichi, Japan
[17] Pfizer Inc, Cambridge, MA USA
[18] Pfizer Inc, New York, NY USA
[19] Pfizer SLU, Madrid, Spain
[20] Mem Sloan Kettering Canc Ctr, Div Hematol & Oncol, Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8039
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Raje, Noopur S.
    Jakubowiak, Andrzej
    Gasparetto, Cristina
    Cornell, Robert F.
    Krupka, Heike I.
    Navarro, Daniel
    Forgie, Alison J.
    Udata, Chandrasekhar
    Basu, Cynthia
    Chou, Jeffrey
    Leung, Abraham
    Lesokhin, Alexander M.
    BLOOD, 2019, 134
  • [22] Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
    Nooka, Ajay K.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Niesvizky, Ruben
    Maisel, Christopher
    Arnulf, Bertrand
    Larson, Sarah Marie
    Yanovsky, Asya Varshavsky
    Leleu, Xavier P.
    Karlin, Lionel
    Vesole, David H.
    Bahlis, Nizar J.
    de Larrea, Carlos Fernandez
    Raje, Noopur S.
    Leip, Eric
    Conte, Umberto
    Elmeliegy, Mohamed
    Viqueira, Andrea
    Manier, Salomon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Pooled Analysis of MagnetisMM Studies: Efficacy and Safety of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Previously Exposed to B-cell Maturation Antigen (BCMA)-Directed Therapies
    Ajay, Nooka K.
    Alexander, Lesokhin M.
    Mahamad, Mohty
    Ruben, Niesvizky
    Christopher, Maisel
    Bertrand, Arnulf
    Sarah, Larson M.
    Nina, Asya Varshavsky-Yanovsky
    Xavier, Leleu
    Lionel, Karlin
    David, Vesole H.
    Nizar, Bahlis J.
    de Larrea Carlos, Fernandez
    Noopur, Raje
    Eric, Leip
    Umbarto, Conte
    Mohamed, Elmeliegy
    Andrea, Viqueira
    Saloman, Manier
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S27 - S28
  • [24] Efficacy and Safety of Elranatamab by Age and Frailty in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Subgroup Analysis From MagnetisMM-3
    Raje, Noopur
    Leleu, Xavier
    Lesokhin, Alexander
    Mohty, Mohamad
    Nooka, Ajay K.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Manier, Salomon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S497
  • [25] Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies
    Elmeliegy, Mohamed
    Lon, Hoi Kei
    Wang, Diane
    Ma, Wei An
    King, Lindsay
    Viqueira, Andrea
    Czibere, Akos
    BLOOD, 2023, 142
  • [26] Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
    Krishnan, Amrita Y.
    Garfall, Alfred L.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Karlin, Lionel
    Benboubker, Lotfi
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Goldberg, Jenna D.
    Banerjee, Arnob
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Lesokhin, Alexander M.
    Levy, Moshe Y.
    Dalovisio, Andrew P.
    Bahlis, Nizar J.
    Solh, Melhem
    Sebag, Michael
    Jakubowiak, Andrzej
    Jethava, Yogesh S.
    Costello, Caitlin L.
    Chu, Michael P.
    Savona, Michael R.
    Gasparetto, Cristina
    Trudel, Suzanne
    Chou, Jeffrey
    Udata, Chandrasekhar
    Basu, Cynthia
    Krupka, Heike I.
    Raje, Noopur S.
    BLOOD, 2020, 136
  • [28] POPULATION PHARM ACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) x CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Polepally, A.
    Badillo, J.
    Rinas, M.
    Ahsan, A.
    Bueno, O.
    Talati, C.
    Menon, R.
    Engelhardt, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
  • [29] Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).
    Usmani, Saad Zafar
    Mateos, Maria-Victoria
    Nahi, Hareth
    Krishnan, Amrita Y.
    van de Donk, Niels W. C. J.
    San Miguel, Jesus
    Oriol, Albert
    Rosinol, Laura
    Chari, Ajai
    Adams, Homer
    Girgis, Suzette
    Lin, Shun Xin Wang
    Stephenson, Tara
    Kemmerer, Kristy
    Smit, Jennifer
    Elsayed, Yusri A.
    Infante, Jeffrey R.
    Goldberg, Jenna D.
    Banerjee, Arnob
    Garfall, Alfred L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    Ahsan, Aarif
    Mantis, Christine
    Luo, Xizhi
    Zhang, Catherine C.
    Valdes, Cesar Rodriguez
    Voorhees, Peter M.
    D'Souza, Anita
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Mckay, John T.
    Weisel, Katja C.
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Kumar, Shaji
    Bueno, Orlando Felix
    Pothacamury, Rajvineeth Kumar
    Talati, Chetasi
    Ross, Jeremy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345